>>The alpha penalty for upsizing is something that could presumably be negotiated with the FDA.
Maybe one of the stats gurus could chime in, but changing the size of the trial based on the degree of efficacy already shown (as opposed to number of events etc.) seems above and beyond a typical alpha spend calculation.
Market Data 
Markets 
AI
